X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• KeyBanc Reiterates Overweight Rating on Brinker Int'l (EAT)
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)